(Q36752014)

16 August 2017

1 reference

title

Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma (English)

1 reference

16 August 2017

1 reference

Bridgette Collins-Burow

series ordinal

1

1 reference

PubMed ID

17338647

16 August 2017

Edgardo S Santos

series ordinal

2

1 reference

16 August 2017

1 March 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

257-273

1 reference

16 August 2017

3

1 reference

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Treatment of IgM antibody associated polyneuropathies using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

B cell depletion therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Selective internalization of monoclonal antibodies by B‐cell chronic lymphocytic leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

CD20: a regulator of cell-cycle progression of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Rituximab: mechanism of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

The mechanisms of action of rituximab in the elimination of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Safety of rituximab maintenance therapy in follicular lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Patient benefits of maintenance immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.257

21 January 2018

Identifiers

DOI

10.1586/14737140.7.3.257

1 reference

16 August 2017

1 reference

PubMed ID

17338647